Search research articles
Contact Us
Filters
Showing results (71-80 of 91) with videos related to
Page
of 10
Sort By:
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer
|
July 2, 2017
The influence of unmet supportive care needs on anxiety and depression during cancer treatment and beyond: a longitudinal study of survivors of haematological cancers
Devesh Oberoi, Victoria M White, John F Seymour, et al.
British Journal of Haematology
|
July 12, 2022
Predictors of early mortality in multiple myeloma: Results from the Australian and New Zealand Myeloma and Related Diseases Registry (MRDR)
Zoe McQuilten, Cameron Wellard, Elizabeth Moore, et al.
Medrxiv : the Preprint Server for Health Sciences
|
November 19, 2025
Reply to: The chemotherapeutic drug CX-5461 is a potent mutagen in cultured human cells
Sehrish Kanwal, Natalie Brajanovski, Jiajun Zhan, et al.
The Journal of Pastoral Care & Counseling : JPCC
|
December 21, 2021
Chaplain Leadership During COVID-19: An International Expert Panel
Csaba Szilagyi, Anne Vandenhoeck, Megan C Best, et al.
Haematologica
|
October 14, 2011
Response of myeloma to the proteasome inhibitor bortezomib is correlated with the unfolded protein response regulator XBP-1
Silvia C W Ling, Edwin K K Lau, Ammira Al-Shabeeb, et al.
European Journal of Haematology
|
August 24, 2017
Distress and unmet needs during treatment and quality of life in early cancer survivorship: A longitudinal study of haematological cancer patients
Devesh V Oberoi, Victoria M White, John F Seymour, et al.
Internal Medicine Journal
|
August 5, 2025
Management of patients with newly diagnosed multiple myeloma who are eligible for autologous stem cell transplantation: position statement of the Medical and Scientific Advisory Group of Myeloma Australia
Georgia McCaughan, Hayley Beer, Christian Bryant, et al.
Internal Medicine Journal
|
January 8, 2026
Treatment of patients with newly diagnosed multiple myeloma who are ineligible for autologous stem cell transplantation: position statement of the Myeloma Foundation of Australia Medical and Scientific Advisory Group
Shirlene Sim, Georgia McCaughan, Andrew Zannettino, et al.
British Journal of Haematology
|
February 16, 2017
Upfront lower dose lenalidomide is less toxic and does not compromise efficacy for vulnerable patients with relapsed refractory multiple myeloma: final analysis of the phase II RevLite study
Hang Quach, Liam Fernyhough, Ross Henderson, et al.
Clinical Lymphoma, Myeloma & Leukemia
|
January 13, 2026
Cytogenetic Testing in Newly Diagnosed Multiple Myeloma: Real World Evidence on Clinical Features and Adverse Outcomes for High Risk Groups
Ghassan Zammar, Bradley Augustson, Elizabeth Moore, et al.
Page
of 10
Search research articles
Search
Showing results (71-80 of 91) with videos related to
Sort By:
Page
of 10
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer
|
July 2, 2017
The influence of unmet supportive care needs on anxiety and depression during cancer treatment and beyond: a longitudinal study of survivors of haematological cancers
Devesh Oberoi, Victoria M White, John F Seymour, et al.
British Journal of Haematology
|
July 12, 2022
Predictors of early mortality in multiple myeloma: Results from the Australian and New Zealand Myeloma and Related Diseases Registry (MRDR)
Zoe McQuilten, Cameron Wellard, Elizabeth Moore, et al.
Medrxiv : the Preprint Server for Health Sciences
|
November 19, 2025
Reply to: The chemotherapeutic drug CX-5461 is a potent mutagen in cultured human cells
Sehrish Kanwal, Natalie Brajanovski, Jiajun Zhan, et al.
The Journal of Pastoral Care & Counseling : JPCC
|
December 21, 2021
Chaplain Leadership During COVID-19: An International Expert Panel
Csaba Szilagyi, Anne Vandenhoeck, Megan C Best, et al.
Haematologica
|
October 14, 2011
Response of myeloma to the proteasome inhibitor bortezomib is correlated with the unfolded protein response regulator XBP-1
Silvia C W Ling, Edwin K K Lau, Ammira Al-Shabeeb, et al.
European Journal of Haematology
|
August 24, 2017
Distress and unmet needs during treatment and quality of life in early cancer survivorship: A longitudinal study of haematological cancer patients
Devesh V Oberoi, Victoria M White, John F Seymour, et al.
Internal Medicine Journal
|
August 5, 2025
Management of patients with newly diagnosed multiple myeloma who are eligible for autologous stem cell transplantation: position statement of the Medical and Scientific Advisory Group of Myeloma Australia
Georgia McCaughan, Hayley Beer, Christian Bryant, et al.
Internal Medicine Journal
|
January 8, 2026
Treatment of patients with newly diagnosed multiple myeloma who are ineligible for autologous stem cell transplantation: position statement of the Myeloma Foundation of Australia Medical and Scientific Advisory Group
Shirlene Sim, Georgia McCaughan, Andrew Zannettino, et al.
British Journal of Haematology
|
February 16, 2017
Upfront lower dose lenalidomide is less toxic and does not compromise efficacy for vulnerable patients with relapsed refractory multiple myeloma: final analysis of the phase II RevLite study
Hang Quach, Liam Fernyhough, Ross Henderson, et al.
Clinical Lymphoma, Myeloma & Leukemia
|
January 13, 2026
Cytogenetic Testing in Newly Diagnosed Multiple Myeloma: Real World Evidence on Clinical Features and Adverse Outcomes for High Risk Groups
Ghassan Zammar, Bradley Augustson, Elizabeth Moore, et al.
Page
of 10